Qian Chen, Guangyi Gao, Ying Yuan, Yan Zong, Xiaofeng Zhao, Hai Guo
{"title":"紫杉醇联合奥沙利铂治疗晚期原发性肝细胞癌的疗效和安全性。","authors":"Qian Chen, Guangyi Gao, Ying Yuan, Yan Zong, Xiaofeng Zhao, Hai Guo","doi":"10.62347/ZKIG9938","DOIUrl":null,"url":null,"abstract":"<p><p>Primary liver cancer (PLC) often presents with subtle early symptoms, leading to most diagnoses at advanced stages, which negatively impacts treatment outcomes. This study evaluated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) combined with Oxaliplatin (OXA) in the treatment of advanced PLC patients without surgical indications. A total of 126 patients with advanced PLC were divided into two treatment groups: the nab-PTX/OXA group (n=66) and the sorafenib (Sor)/OXA group (n=60), with a treatment cycle of 21 days. Clinical response rates, sleep quality (SQ), quality of life (QoL), prognosis, and adverse reactions were compared between the two groups. The results indicated that, after treatment, the nab-PTX/OXA group demonstrated significantly higher objective response rate, sleep quality (PSQI score), and QoL (SF-36 score) compared to the Sor/OXA group (all <i>P</i><0.05). Both groups demonstrated significant increases in Cluster of Differentiation 3-positive (CD3+) and CD4+ cell levels at Day 21 compared to Day 0 (<i>P</i><0.05), with a greater increase observed in the nab-PTX/OXA group (<i>P</i><0.05). Conversely, CD8+ cell levels were significantly decreased at Day 21 compared to Day 0 in both groups (<i>P</i><0.05), with a more pronounced decrease in the nab-PTX/OXA group (<i>P</i><0.05). Additionally, the CD4+/CD8+ ratio was significantly elevated at Day 21 compared to Day 0 in both groups (<i>P</i><0.05), with a greater increase observed in the Sor/OXA group (<i>P</i><0.05). Furthermore, the overall survival (OS) and progression-free survival (PFS) in the nab-PTX/OXA group were significantly longer than those in the Sor/OXA group (<i>P</i><0.05). In the nab-PTX/OXA group, the incidence of abdominal pain and diarrhea, grade III-IV leukopenia, thrombocytopenia, and liver and kidney dysfunction was significantly lower than that in the Sor/OXA group (<i>P</i><0.05). In short, PTX combined with OXA demonstrated favorable efficacy in treating advanced PLC. This regimen not only improved SQ and QoL but also prolonged survival.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1122-1132"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982741/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of paclitaxel combined with oxaliplatin in the treatment of advanced primary hepatocellular carcinoma.\",\"authors\":\"Qian Chen, Guangyi Gao, Ying Yuan, Yan Zong, Xiaofeng Zhao, Hai Guo\",\"doi\":\"10.62347/ZKIG9938\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Primary liver cancer (PLC) often presents with subtle early symptoms, leading to most diagnoses at advanced stages, which negatively impacts treatment outcomes. This study evaluated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) combined with Oxaliplatin (OXA) in the treatment of advanced PLC patients without surgical indications. A total of 126 patients with advanced PLC were divided into two treatment groups: the nab-PTX/OXA group (n=66) and the sorafenib (Sor)/OXA group (n=60), with a treatment cycle of 21 days. Clinical response rates, sleep quality (SQ), quality of life (QoL), prognosis, and adverse reactions were compared between the two groups. The results indicated that, after treatment, the nab-PTX/OXA group demonstrated significantly higher objective response rate, sleep quality (PSQI score), and QoL (SF-36 score) compared to the Sor/OXA group (all <i>P</i><0.05). Both groups demonstrated significant increases in Cluster of Differentiation 3-positive (CD3+) and CD4+ cell levels at Day 21 compared to Day 0 (<i>P</i><0.05), with a greater increase observed in the nab-PTX/OXA group (<i>P</i><0.05). Conversely, CD8+ cell levels were significantly decreased at Day 21 compared to Day 0 in both groups (<i>P</i><0.05), with a more pronounced decrease in the nab-PTX/OXA group (<i>P</i><0.05). Additionally, the CD4+/CD8+ ratio was significantly elevated at Day 21 compared to Day 0 in both groups (<i>P</i><0.05), with a greater increase observed in the Sor/OXA group (<i>P</i><0.05). Furthermore, the overall survival (OS) and progression-free survival (PFS) in the nab-PTX/OXA group were significantly longer than those in the Sor/OXA group (<i>P</i><0.05). In the nab-PTX/OXA group, the incidence of abdominal pain and diarrhea, grade III-IV leukopenia, thrombocytopenia, and liver and kidney dysfunction was significantly lower than that in the Sor/OXA group (<i>P</i><0.05). In short, PTX combined with OXA demonstrated favorable efficacy in treating advanced PLC. This regimen not only improved SQ and QoL but also prolonged survival.</p>\",\"PeriodicalId\":7437,\"journal\":{\"name\":\"American journal of cancer research\",\"volume\":\"15 3\",\"pages\":\"1122-1132\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982741/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.62347/ZKIG9938\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/ZKIG9938","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Efficacy and safety of paclitaxel combined with oxaliplatin in the treatment of advanced primary hepatocellular carcinoma.
Primary liver cancer (PLC) often presents with subtle early symptoms, leading to most diagnoses at advanced stages, which negatively impacts treatment outcomes. This study evaluated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) combined with Oxaliplatin (OXA) in the treatment of advanced PLC patients without surgical indications. A total of 126 patients with advanced PLC were divided into two treatment groups: the nab-PTX/OXA group (n=66) and the sorafenib (Sor)/OXA group (n=60), with a treatment cycle of 21 days. Clinical response rates, sleep quality (SQ), quality of life (QoL), prognosis, and adverse reactions were compared between the two groups. The results indicated that, after treatment, the nab-PTX/OXA group demonstrated significantly higher objective response rate, sleep quality (PSQI score), and QoL (SF-36 score) compared to the Sor/OXA group (all P<0.05). Both groups demonstrated significant increases in Cluster of Differentiation 3-positive (CD3+) and CD4+ cell levels at Day 21 compared to Day 0 (P<0.05), with a greater increase observed in the nab-PTX/OXA group (P<0.05). Conversely, CD8+ cell levels were significantly decreased at Day 21 compared to Day 0 in both groups (P<0.05), with a more pronounced decrease in the nab-PTX/OXA group (P<0.05). Additionally, the CD4+/CD8+ ratio was significantly elevated at Day 21 compared to Day 0 in both groups (P<0.05), with a greater increase observed in the Sor/OXA group (P<0.05). Furthermore, the overall survival (OS) and progression-free survival (PFS) in the nab-PTX/OXA group were significantly longer than those in the Sor/OXA group (P<0.05). In the nab-PTX/OXA group, the incidence of abdominal pain and diarrhea, grade III-IV leukopenia, thrombocytopenia, and liver and kidney dysfunction was significantly lower than that in the Sor/OXA group (P<0.05). In short, PTX combined with OXA demonstrated favorable efficacy in treating advanced PLC. This regimen not only improved SQ and QoL but also prolonged survival.
期刊介绍：
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
